Annual and transition report of foreign private issuers pursuant to Section 13 or 15(d)


12 Months Ended
Mar. 31, 2022
Asbestos [Abstract]  
Asbestos Asbestos
The AFFA was approved by shareholders in February 2007 to provide long-term funding to AICF. For a discussion of the AFFA and the accounting policies utilized by the Company related to the AFFA and AICF, see Note 1.
Asbestos Adjustments loss
The Asbestos adjustments loss included in the consolidated statements of operations and comprehensive income comprise the following:
  Years Ended 31 March
(Millions of US dollars) 2022 2021 2020
Change in estimates:
Change in actuarial estimate - asbestos liability $ 145.6  $ 33.0  $ 133.8 
Change in actuarial estimate - insurance receivable (5.3) (2.0) (5.7)
Change in estimate - AICF claims-handling costs 0.6  1.5  (0.1)
Subtotal - Change in estimates 140.9  32.5  128.0 
Effect of foreign exchange on Asbestos net liabilities (13.2) 123.0  (69.0)
Loss (gain) on foreign currency forward contracts 5.3  (11.7) (0.8)
Other (1.3) 0.1  — 
Asbestos adjustments loss $ 131.7  $ 143.9  $ 58.2 
Actuarial Study; Claims Estimate
AICF commissioned an updated actuarial study of potential asbestos-related liabilities as of 31 March 2022. Based on KPMGA’s assumptions, KPMGA arrived at a range of possible total cash flows and calculated a central estimate, which is intended to reflect a probability-weighted expected outcome of those actuarial estimated future cash flows.
The following table sets forth the central estimates, net of insurance recoveries, calculated by KPMGA as of 31 March 2022:
Year Ended 31 March 2022
(Millions of US and Australian dollars, respectively) US$  A$
Central Estimate – Discounted and Inflated 1,213.8  1,622.3 
Central Estimate – Undiscounted but Inflated 1,499.1  2,003.6 
Central Estimate – Undiscounted and Uninflated 1,040.0  1,389.9 
The asbestos liability has been revised to reflect the most recent undiscounted and uninflated actuarial estimate prepared by KPMGA as of 31 March 2022.
In estimating the potential financial exposure, KPMGA has made a number of assumptions, including, but not limited to, assumptions related to the peak period of claims, total number of claims that are reasonably estimated to be asserted through 2073, the typical cost of settlement (which is sensitive to, among other factors, the industry in which a plaintiff claims exposure, the alleged disease type, the age of the claimant and the jurisdiction in which the action is brought), the legal costs incurred in the litigation of such claims, the rate of receipt of claims, the settlement strategy in dealing with outstanding claims and the timing of settlements. Changes to the assumptions may be necessary in future periods should mesothelioma claims reporting escalate or decline.
Due to inherent uncertainties in the legal and medical environment, the number and timing of future claim notifications and settlements, the recoverability of claims against insurance contracts, and estimates of future trends in average claim awards, as well as the extent to which the above named entities will contribute to the overall settlements, the actual liability could differ materially from that which is currently recorded.
The potential range of costs as estimated by KPMGA is affected by a number of variables such as nil settlement rates, peak year of claims, past history of claims numbers, average settlement rates, past history of Australian asbestos-related medical injuries, current number of claims, average defense and plaintiff legal costs, base wage inflation and superimposed inflation. The potential range of losses disclosed includes both asserted and unasserted claims.
A sensitivity analysis was performed by KPMGA to determine how the actuarial estimates would change if certain assumptions (i.e., the rate of inflation and superimposed inflation, the average costs of claims and legal fees, and the projected numbers of claims) were different from the assumptions used to determine the central estimates. The sensitivity analysis performed in the actuarial report is directly related to the discounted but inflated central estimate and the undiscounted but inflated central estimate. The actual cost of the liabilities could be outside of that range depending on the results of actual experience relative to the assumptions made.
The following table summarizes the results of the analysis:
As of 31 March 2022
(Millions of US and Australian dollars, respectively) US$ A$
Discounted (but inflated) - Low
932.8  1,246.7 
Discounted (but inflated) - High
1,914.8  2,559.1 
Undiscounted (but inflated) - Low
1,131.5  1,512.2 
Undiscounted (but inflated) - High
2,471.2  3,302.8 
Potential variation in the estimated peak period of claims has an impact much greater than the other assumptions used to derive the discounted central estimate. In performing the sensitivity assessment of the estimated incidence pattern reporting for mesothelioma, if the pattern of incidence was shifted by two years, the central estimate could increase by approximately 21% on a discounted basis.
Claims Data
The following table shows the activity related to the numbers of open claims, new claims and closed claims during each of the past five years and the average settlement per settled claim and case closed:
  For the Years Ended 31 March
   2022 2021 2020 2019 2018
Number of open claims at beginning of period 360  393  332  336  352 
Number of new claims
Direct claims 411  392  449  430  422 
Cross claims 144  153  208  138  140 
Number of closed claims 550  578  596  572  578 
Number of open claims at end of period 365  360  393  332  336 
Average settlement amount per settled claim A$314,000 A$248,000 A$277,000 A$262,000 A$253,000
Average settlement amount per case closed 1
A$282,000 A$225,000 A$245,000 A$234,000 A$217,000
Average settlement amount per settled claim US$232,000 US$178,000 US$189,000 US$191,000 US$196,000
Average settlement amount per case closed 1
US$208,000 US$162,000 US$167,000 US$171,000 US$168,000
 1 The average settlement amount per case closed includes nil settlements.
During fiscal year 2022, mesothelioma claims reporting activity was 1% above actuarial expectations and 3% unfavorable compared to the prior corresponding period. Average claim sizes were higher than expectations for direct claims and lower than expectations for cross claims. Net cash outflow was 1% below actuarial expectations.
Under the terms of the AFFA, the Company has rights of access to actuarial information produced for AICF by the actuary appointed by AICF, which is currently KPMGA. The Company’s disclosures with respect to claims statistics are subject to it obtaining such information, however, the AFFA does not provide the Company an express right to audit or otherwise require independent verification of such information or the methodologies to be adopted by the approved actuary. As such, the Company relies on the accuracy and completeness of the information provided by AICF to the approved actuary and the resulting information and analysis of the approved actuary when making disclosures with respect to claims statistics.
The following is a detailed rollforward of the Net Unfunded AFFA liability, net of tax, for the fiscal year ended 31 March 2022:
(Millions of US dollars)   Asbestos   Liability    Insurance
Cash and Investments
and Liabilities
Net Unfunded AFFA Liability Deferred Tax
Net Unfunded AFFA Liability, net of tax
Opening Balance - 31 March 2021 $ (1,135.8) $ 49.5  $ 131.5  $ (1.9) $ (956.7) $ 367.4  $ 35.2  $ (554.1)
Asbestos claims paid1
117.6  —  (117.6) —  —  —  —  — 
Payment received in accordance with AFFA —  —  248.5  —  248.5  —  —  248.5 
AICF claims-handling costs incurred (paid) 1.2  —  (1.2) —  —  —  —  — 
AICF operating costs paid - non claims-handling —  —  (1.3) —  (1.3) —  —  (1.3)
Change in actuarial estimate (145.6) 5.3  —  —  (140.3) —  —  (140.3)
Change in claims handling cost estimate (0.6) —  —  —  (0.6) —  —  (0.6)
Impact on deferred income tax due to change in actuarial estimate —  —  —  —  —  42.3  —  42.3 
Insurance recoveries —  (8.3) 8.3  —  —  —  —  — 
Movement in income tax payable —  —  —  —  —  (43.3) 8.4  (34.9)
Other movements —  —  (7.4) 1.0  (6.4) 0.1  —  (6.3)
Effect of foreign exchange 19.5  (0.8) 0.8  (0.2) 19.3  (6.4) 0.3  13.2 
Closing Balance - 31 March 2022 $ (1,143.7) $ 45.7  $ 261.6  $ (1.1) $ (837.5) $ 360.1  $ 43.9  $ (433.5)
1Claims paid of US$117.6 million reflects A$159.1 million converted at the average exchange rate for the period based on the assumption that these transactions occurred evenly throughout the period.
AICF Funding
In accordance with the terms of the AFFA, the Company anticipates that it will contribute approximately A$157.5 million (US$117.8 million based on the exchange rate at 31 March 2022) to AICF during the fiscal year ending 31 March 2023.
During the fiscal years ended 31 March 2022, 2021 and 2020, the Company contributed US$248.5 million (A$328.2 million), US$153.3 million (A$220.9 million) and US$108.9 million (A$156.7 million), respectively, to AICF.
Restricted Short-Term Investments
AICF invests its excess cash in time deposits, which are classified as available-for-sale investments until maturity. The following table represents the investments entered into or maturing during the fiscal year ended 31 March 2022:
Date Invested Maturity Date Interest Rate A$ Millions
January 2022 25 January 2024 1.41% 30.0
January 2022 25 January 2023 0.79% 100.0
October 2021 6 October 2023 0.60% 30.0
October 2020 2 July 2021 0.59% 35.0
At 31 March 2022, AICF’s short-term investments were revalued resulting in a mark-to-market fair value adjustment of nil.
AICF – NSW Government Secured Loan Facility
AICF may borrow, subject to certain conditions, up to an aggregate amount of A$320.0 million (US$239.4 million, based on the exchange rate at 31 March 2022). The AICF Loan Facility is guaranteed by the Former James Hardie Companies and is available to be drawn for the payment of claims through 1 November 2030, at which point, all outstanding borrowings must be repaid. At 31 March 2022 and 2021, AICF had no amounts outstanding under the AICF Loan Facility.